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The vaccine against yellow fever is one of the safest and most effective ever 
developed. With an outstanding record in humans, has this live attenuated 
vaccine been overlooked as a promising vector for the development of vaccines 
against pathogens outside its own genus? Recent studies, including a report by 
Tao et al. on page 201 of this issue, have sparked renewed interest.
 
The yellow fever vaccine has already
been used with great success to create
vaccines against yellow fever’s close rela-
tives, the RNA-based flaviviruses. Re-
cent successes with other yellow fever–
based vaccines, combined with increased
interest in the basic immunology of the
virus, provide new hope that this nearly
century-old vaccine vector may provide
the basis for protecting against not just
flaviviruses but also unrelated pathogens
for which effective vaccines have yet to
be developed.
 
Yellow fever basics
 
Yellow fever virus is a flavivirus that is
transmitted between monkeys, humans,
and mosquitos, and survives dry seasons
in mosquito eggs—a transmission cycle
that makes eradicating this virus virtually
impossible. Causing illness and death at
1000-fold greater incidence than Ebola,
with equally terrifying symptoms, yellow
fever is one of the most lethal viral infec-
tions known to man. The virus, endemic
to tropical Africa and South America,
causes hemorrhage, multiorgan failure,
and shock and is lethal in 20–50% of
severe cases (1). Yellow fever virus infects
cells of multiple organs, but beyond that
knowledge of the basic biology of the
virus is slim.
Development of the yellow fever
virus vaccine began in 1930 when Max
Theiler and his colleagues at the Rocke-
feller Foundation created the first attenu-
ated strains of yellow fever by growing
the virus in tissue culture for over 200
generations (2), an accomplishment that
earned Theiler the Nobel Prize in 1951.
Since the 1930s, Theiler’s vaccine strain,
known as 17D, has been administered to
over 400 million individuals and caused
only rare severe side effects or death (3).
The efficacy of this vaccine is most evi-
dent in certain parts of Africa, where yel-
low fever virtually disappeared between
1939 and 1952 due to mass immuniza-
tion programs.
After a single inoculation, the yellow
fever vaccine elicits robust protection
that is sustained for decades and possi-
bly for life. Given its proven immuno-
genicity and safety, the yellow fever
17D strain seems an ideal choice as a
vector for other vaccines. Although
huge gaps in our knowledge remain,
including the reasons why 17D is so
effective, new studies are getting 17D
plenty of attention.
 
Vector choice
 
What makes a good vector? The
requirements include immunogenicity,
safety, large cloning capacity, and genetic
stability. In other words, an ideal vector
stimulates a robust immune response
that provides long-lasting protection
against infection, does not make people
sick, readily accepts the introduction of
foreign sequences into its genome, and
tolerates these genetic squatters over
time without evicting them. From a
clinical standpoint, it is also helpful if the
vaccine can be administered in a single
immunization to recipients who have
minimal or no prior immunity to the
vector. This combination is a tall order;
for most if not all applications, the ideal
vector doesn’t exist. With each vector
choice comes the challenge of balanc-
ing multiple factors and identifying the
strengths and weaknesses inherent to
each vector.
 
Immunogenicity and safety of 17D
 
Vaccines should provide large benefits
with low risk. The yellow fever vaccine
does just that by eliciting strong and
long-lasting humoral and cellular immu-
nity in humans with little risk to recipi-
ents. Neutralizing antibodies—the first
line of defense against virus encoun-
tered upon reexposure—develop in
98–100% of yellow fever 17D vaccine
recipients and can be detected for several
decades after vaccination (1). Less is
known about specific T cell responses,
but total numbers of circulating CD8
 
 
 
T cells increase in vaccine recipients (4)
and virus-specific CD8
 
 
 
 T cell responses
have been detected for up to 18 months
after vaccination (5), suggesting that
CD8
 
 
 
 T cells are effectively primed by
the vaccine.
The price paid for effective immunity
is low, as severe complications of the
yellow fever 17D vaccine are rare. Since
1945, postvaccine encephalitis has been
reported in 
 
 
 
1 in 20 million recipients,
Cryo-electron microscope image reconstruction 
of an immature form of yellow fever 17D. Image 
provided by Richard J. Kuhn, Purdue University, 
West Lafayette, IN.
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primarily young children. To avoid this,
children younger than 9 months of age
are not vaccinated. In the past 10 years,
several fatal cases of viscerotropic disease
that resembled natural yellow fever virus
infection were reported after immuniza-
tion, mostly among elderly people. It is
unclear why this serious complication has
cropped up recently, as sequencing of the
virus from these patients failed to identify
mutations that would suggest the emer-
gence of a variant virus. These cases are a
major concern, and understanding why
these complications occur in some indi-
viduals may be a prerequisite to wide-
spread use of a 17D-based vaccine.
 
“It may be smarter to start with an 
existing vaccine that we already know 
 
works.”
 
Other highly immunogenic vectors
are even more risky. Vaccinia virus, an
attenuated poxvirus used for centuries to
vaccinate against smallpox, also elicits
potent and possibly life-long immunity
in humans. But the risks include over-
whelming infection, encephalitis, and
brain infection, and are considerably
higher  than those associated with the
yellow fever vaccine. As a safer alterna-
tive, replication-deficient strains of vac-
cinia virus are now favored for use in
humans. Replication-deficient vaccinia
viruses carrying HIV antigens, for exam-
ple, have been shown to be well toler-
ated and to stimulate virus-specific im-
mune responses in primates. But the
safety gain is outweighed by loss in im-
munogenicity, as these vectors raise only
moderate neutralizing antibody and T
cell responses in a fraction of recipients.
Adenovirus vectors are likely to
prime strong immune responses, as
they can replicate in many cell types
including mucosal cells and professional
antigen-presenting cells. Recombinant
adenoviruses are highly immunogenic
in animals but not in humans, where
they face the formidable barrier of pre-
existing adenovirus-specific immunity,
which causes the vector to be elimi-
nated before an immune response to
the foreign antigen can develop.
The immunogenicity and safety of
many other live recombinant virus vec-
tors are still being evaluated. Even if
these vectors prove to be safe and immu-
nogenic in animals, a robust immune re-
sponse in mice, or even monkeys, does
not necessarily translate to a similar re-
sponse in humans. For yellow fever,
safety and immunogenicity are known
commodities. “There has already been a
huge experiment to test safety in hu-
mans, one that could never be repeated,”
says Raul Andino (University of Califor-
nia, San Francisco, San Francisco, CA).
Rather than design a vaccine from
scratch, Andino points out that it may be
smarter to start with an existing vaccine
that we already know works.
 
Capacity to carry new genes
 
Vector choice also hinges on the ability
of a vector to carry foreign gene se-
quences without rejecting them over
time and without losing infectivity.
Unfortunately, the vectors that are the
easiest to grow in the laboratory and
will accept large amounts of foreign
DNA are not necessarily the safest or
most immunogenic in humans.
DNA viruses, such as poxviruses
and adenoviruses, tolerate both the in-
sertion of multiple large foreign genes
and the loss of large pieces of their own
DNA without losing infectivity. Both
poxviruses and adenoviruses are also
easy to grow in the lab and replicate in
many different cell types. But Andino
suggests that many scientists choose
DNA vaccine vectors primarily because
they are lab friendly, and thus overlook
better choices.
RNA viruses are more resistant to
the introduction of large foreign genes
than their DNA counterparts, mostly
because of their small size and relative
instability. “Flaviviruses are very small
and are not very tolerant of things out-
side the flavivirus genus,” says Tom
Monath (Acambis, Cambridge, MA).
“Sometimes the genes get kicked out
after a while.” Many consider the size
of the yellow fever virus to be its
Achilles heel, although the limit on
introducing genetic information into
17D—both in terms of location and
amount—remains to be determined.
Despite this, short foreign sequences
have been expressed in yellow fever
and other small RNA viruses and have
been shown to be stable over many
passages. There are also ways around
the limits on insertion size—including
tricks like using bicistronic constructs
containing internal ribosomal entry sites
(IRES)—that may allow for the intro-
duction of longer sequences.
 
The problem of antivector immunity
 
As previously mentioned, adenovirus
suffers from the problem of preexisting
immunity, and widespread vaccination
against smallpox also burdens vaccinia
virus as a vector. Similarly, a yellow fe-
ver–based vaccine carrying, for exam-
ple, HIV epitopes might struggle in
yellow fever endemic regions of Cen-
tral and South America where immu-
nization rates against 17D approach
90%. Such a vaccine could, however,
be useful in the US (where only travel-
ers are vaccinated) and Africa (where
only 1–40% of people are vaccinated).
A vaccine that would benefit African
populations—especially one with the
potential to immunize against both yel-
low fever and another endemic patho-
gen—would be particularly useful.
 
“Flaviviruses are very small and are 
not very tolerant of things outside the 
 
flavivirus genus.”
 
It is unclear whether existing immu-
nity to yellow fever, or a yellow fever–
based vaccine, would preclude the use
of another vaccine that has a yellow fe-
ver 17D backbone. Francis Ennis (Uni-
versity of Massachusetts Medical Cen-
ter, Worcester, MA
 
)
 
 and his group are
actively addressing this question by ad-
ministering new 17D-based vaccines to
volunteers and comparing the responses
of people who have or have not previ-
ously received a 17D-based vaccine.
 
Replication location
 
One reason 17D works so well is sim-
ply that it is a live attenuated virus.
“Because they have the replication ma-
chinery of live viruses, they basically
become virus factories,” explains Ennis.
Replication location also matters.
17D probably replicates where the
wild-type virus replicates and stimu-
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lates the same kinds of immunity.
Thus, it elicits an immune response
that is well targeted against yellow fe-
ver virus itself. But if 17D is to be used
as a vector for other microbial patho-
gens, we need to learn more about the
possible match between 17D-generated
immunity and the other infections, in
terms of both replication sites and
mechanisms. Potent mucosal immunity
against a sexually transmitted pathogen
like HIV, for example, would be most
readily generated if the vaccine vector
generates immune responses that target
HIV-infected cells in the mucosa.
For yellow fever virus, much of this
information is lacking. And although in-
fectious virus can be measured in the
blood of vaccine recipients for only a
few days after immunization, no data ex-
ist on the persistence of viral antigens or
the possibility of chronic infection. Rafi
Ahmed (Emory University, Atlanta, GA)
is now studying yellow fever virus in
mice to determine the in vivo targets of
infection. His group is also assessing in-
nate immune signals that emanate from
Toll-like receptors (TLRs) expressed on
antigen presenting cells as a result of in-
fection. Ahmed thinks that the ability of
the virus to infect dendritic cells and
stimulate TLR-dependent production of
cytokines might in part explain why this
vaccine stimulates such robust and dura-
ble T and B cell immunity.
Assessment of vaccine behavior de-
pends on the ability to monitor and
evaluate the immune responses that
arise after vaccination. Virus-specific
antibodies have long been detected in
the blood using standard immunoassays
and plaque assays. But tracking virus-
specific T cells is more difficult and re-
quires an understanding of the specific-
ity of these cells.
Vaccination with 17D has been
shown to activate and expand CD8
 
 
 
 T
cells, but the details are sparse. Ennis’
group identified the first T cell epitopes
on 17D that human CD8
 
 
 
 T cells rec-
ognize on infected cells (5). After vac-
cination with 17D, CD8
 
 
 
 cells specific
for these epitopes were expanded and
could be detected for at least 18
months. Ahmed recently launched a
large study of first-time vaccine recipi-
ents and is monitoring the kinetics of
the virus-specific antibody and T cell
responses induced by vaccination. His
group has identified additional CD8
 
 
 
T cell epitopes on the virus. Sorting of
these cells will allow tests of their effec-
tor function and in vivo monitoring
using peptide-based techniques.
 
17D and flavivirus vaccines
 
In 1989, Charles Rice (Rockefeller
University, New York, NY) and col-
leagues cloned the entire yellow fever
genome as cDNA into bacterial plas-
mids (6). This cDNA was then tran-
scribed back into RNA and transfected
into cells, resulting in the production of
live viral offspring—a difficult feat con-
sidering the instability of the flavivirus
genome in bacterial vectors. The devel-
opment of this “infectious clone” tech-
nology allowed for easier manipulation
of the virus genome and facilitated the
use of 17D as a vaccine vector.
One way to make a vaccine, rather
than inserting individual epitopes into or
between existing viral proteins, is to put
entire foreign coat structures around the
replication machinery of a known vac-
cine vector. Several years after the infec-
tious clone technology was developed,
C.J. Lai and colleagues (National Insti-
tutes of Health, Bethesda, MD) made an
infectious clone of Dengue virus (an-
other flavivirus) and showed that the
structural genes of one serotype of Den-
gue could be replaced by the structural
genes of a different serotype, without
robbing the virus of its ability to infect
cells (7). Rice’s group later used the same
approach with the 17D virus and re-
placed the structural genes with those
from Japanese encephalitis virus, an-
other member of the flavivirus family
(8). These recombinant vectors could
then be used to generate neutralizing an-
tibody responses against the native sur-
face proteins of Dengue or Japanese
encephalitis virus, and thus to protect
against infection.
This “chimeric” virus approach, pi-
oneered by Lai and extended by
Monath and colleagues, was the basis for
successful vaccines against Japanese en-
cephalitis, Dengue, and West Nile virus
(all flaviviruses). All of these vaccines
provide protective immunity in mice
and primates and have moved rapidly
into clinical trials in humans. Monath
stresses that these vaccines progressed
rapidly through clinical trials largely be-
cause the yellow fever backbone is so
reliable. “The balance between safety
and immunogenicity is always the diffi-
culty in developing a live vaccine,” he
says. “We can use the parent (17D vac-
cine) as a benchmark, which facilitates
development and clinical testing.”
 
Vaccines against other pathogens
 
With the success of the chimeric virus
vaccines, why has yellow fever 17D
not been widely used in the develop-
ment of vaccines against other patho-
gens? “I do think that yellow fever has
been neglected to some extent,” says
Rice. This may be changing, however.
In the past few years, vaccines created
by insertion of model antigens or gene
fragments from nonflavivirus pathogens
into yellow fever 17D have elicited ro-
bust immune responses in mice.
A group led by Ricardo Galler
(Fiocruz, Rio de Janeiro, Brazil) per-
formed one “proof of concept” experi-
ment in collaboration with Ruth Nus-
senzweig (New York University, New
York, NY). They inserted an epitope
from the malaria circumsporozoite (CS)
protein—the most abundant protein
expressed on the parasite surface and a
known target of protective antibod-
ies—into the E protein of yellow fever
17D and showed that mice responded
with neutralizing antibodies against
malaria (9).
The 17D strain has also been used to
create a model cancer vaccine in mice
that works by activating cytotoxic T cell
responses capable of eliminating tumor
cells. Andino’s group inserted a CD8
 
 
 
T cell epitope from chicken ovalbumin
between genes in 17D and showed that
the CD8
 
 
 
 T cells activated by this vac-
cine in mice could fight off challenge
with tumor cells expressing the T cell
epitope, even if the tumor was growing
before the vaccination was given (10).
Andino is now developing poten-
tial yellow fever–based HIV vaccines.
He found insertion at several sites in
the 17D genome to be stable and suc-
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cessful, although insertions at other
sites killed the virus. The vaccine can-
didates have been shown to prime po-
tent CD8
 
 
 
 T cell responses against
HIV in mice and monkeys. The CD8
 
 
 
response using a prime–boost ap-
proach in mice, he reports, is 
 
 
 
1000-
fold higher than that achieved with
poxvirus vectors alone. In previous
work, prime–boost strategies using
DNA and attenuated poxvirus vectors
have shown some promising results in
animal models, but have not worked
well in humans, perhaps because the
vectors are not replication competent.
Although safety concerns with live vac-
cines are certainly warranted, Andino
worries that the HIV vaccine field is al-
lowing these concerns to trump the ne-
cessity for immunogenicity.
In a recent collaborative effort led
by the Rice and Nussenzweig teams,
which is reported on page 201 of this
issue, a possible candidate malaria vac-
cine was developed using yellow fever
17D as a backbone (11). The authors
targeted the same insertion position in
17D used by Andino’s group but intro-
duced a CD8
 
 
 
 T cell epitope from the
CS protein of 
 
Plasmodium yoelii
 
, a close
relative of the 
 
Plasmodium
 
 species that
causes human disease. Mice immunized
with this vaccine developed malaria-
specific T cell responses that could pro-
tect them against challenge with live
parasites, even after a single dose. These
T cells could be found in the circulation
for as long as 24 weeks after immuniza-
tion. “The most stunning thing was that
the immune response and protection
lasted so long—after only one immuni-
zation,” says Victor Nussenzweig.
The authors hope to move these ex-
periments into primates soon, and also
plan to test the limits of the yellow fever
genome by inserting multiple T cell
epitopes or the entire CS protein, which
may provide even better immunity.
Yellow fever virus polyprotein showing structural (C, prM, E) and nonstructural (NS1-5) proteins.  The 
location of the malaria CS epitope inserted by Rice and colleagues is shown.
 
They are also considering strategies to
express the whole CS protein on the
surface of the virus as a way of generat-
ing both antibody and T cell responses.
Malaria claims up to three million
lives each year, and the vaccine prob-
lem is far from solved. A vaccine cur-
rently in clinical trials in Africa that also
targets the CS protein was shown to
elicit protective T cell and antibody re-
sponses, but only provided short-term
protection in human volunteers (12).
Immunization with malaria sporozoites
lacking a gene required for liver-stage
growth was recently reported to protect
mice against infection and may provide
an alternative approach to virus-based
vaccine strategies (13). The authors of
the current study hope that their vac-
cine might provide immunity to both
malaria and yellow fever simultaneously
in children who have not yet been vac-
cinated with the yellow fever vaccine.
In this population, antivector immunity
would also not be a factor.
 
The road ahead
 
There are many outstanding questions
regarding the molecular mechanisms
that govern yellow fever virus replica-
tion, the cellular targets of infections,
and the requirements for generating
long-lasting virus-specific immunity.
The answers to these questions will not
only increase our understanding of why
this vaccine is so effective, but will also
allow us to harness its power in search
of better ways to protect against other
deadly pathogens. As 17D is so effec-
tive at stimulating T cell immunity, it
may turn out to be particularly useful
for vaccination against other viruses—
as well as cancer—where attempts to
induce T cell immunity with other
vaccines have failed.
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